secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001720580-26-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio reports Q4 2025 net loss $30.5M; Phase 1 prula-cel enrollment momentum; cash $158.5M
--------------------------------------------------------------------------------

- Net loss Q4 2025: $30.5M ($2.94 per diluted share) compared to $28.7M ($5.06) in Q4 2024.
- Full-year 2025 net loss $116.8M ($16.95 per share) vs $117.1M ($21.33) in 2024.
- Cash, equivalents & investments $158.5M at Dec 31, 2025; expected to fund ops into H2 2027.
- Phase 1 prula-cel autoimmune enrollment ahead; next update H1 2026; pivotal study H2 2026 subject to FDA.
- ADI-212 regulatory filing for mCRPC expected Q3 2026; Phase 1 enrollment Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000172058026000006/0001720580-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000172058026000006/acet-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001720580-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer